Metagenomi Therapeutics, Inc.

Stage 4 · Declining · week 41

As of Oct 22, 2026, Metagenomi Therapeutics is in Stage 4, the downtrend phase, now in week 41 (since Jan 5, 2026). It closed at $0.82, 71.8% below its 52-week high and below its 200-day average, which is falling.

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. More about the company

$0.82

-1.54% today

$30.8M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is MGX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-02-09 → 2026-10-22

S? 41w

S4 16w

S1 15w

S4 42w

2024-02-092026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S4 3w → S1 11w → S4 16w → S1 15w → S2 8w → S3 5w → S4 42w current

Total tracked: 140 weeks across 8 stage runs.

MGX among Biotechnology442nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…442	MGXMetagenomi Therapeutics, Inc.	Stage 4 · wk 41	14	−27.8%

vs 52W High

-71.8%

$0.78 lo$2.89 hi

71.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 41

1w13w26w

Week 41, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-38.3%

200 DMA: $1.32 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.34x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-27.8%

-32.3%

-42.9%

YTD

-51.1%

-74.1%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 41 · Vol 0.34x

2026-10-21S4

Wk 41 · Vol 0.52x

2026-10-20S4

Wk 40 · Vol 0.58x

2026-10-19S4

Wk 40 · Vol 0.96x

2026-10-16S4

Wk 40 · Vol 1.01x

2026-10-15S4

Wk 40 · Vol 1.85x

2026-10-14S4

Wk 40 · Vol 1.91x

2026-10-13S4

Wk 39 · Vol 1.74x

2026-10-12S4

Wk 39 · Vol 0.98x

2026-10-09S4

Wk 39 · Vol 0.98x

2026-10-08S4

Wk 39 · Vol 2.46x

2026-10-07S4

Wk 39 · Vol 1.91x

Moving averages & range

50 DMA

$1.09

200 DMA

$1.32

52W High

$2.89

52W Low

$0.78

5D Low

$0.78

Resistance levels (recent highs)

20d High

$1.15

60d High

$1.24

120d High

$1.43

250d High

$2.89

Next resistance

+40.9%

to 20d High

ROE

-60.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.3

Metagenomi Therapeutics: quick answers

What stage is Metagenomi Therapeutics in?

As of Oct 22, 2026, Metagenomi Therapeutics (MGX) is in Stage 4, the downtrend phase. It entered Stage 4 on Jan 5, 2026 and is in week 41. What the four stages mean

Is Metagenomi Therapeutics in an uptrend?

No. Metagenomi Therapeutics is in a Stage 4 downtrend. It trades 38.3% below its 200-day average, which is falling.

How far is Metagenomi Therapeutics from its 52-week high?

Metagenomi Therapeutics closed at $0.82 on Oct 22, 2026, 71.8% below its 52-week high of $2.89. Its 52-week low is $0.78.

How has Metagenomi Therapeutics performed over the past year?

As of Oct 22, 2026, Metagenomi Therapeutics is down 74.1% over the past year and down 51.1% so far in 2026.

Which sector and industry is Metagenomi Therapeutics in?

Metagenomi Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.